Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmetec, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adults. GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmetec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB that targets the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps lower systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac output. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

Olmesartan medoxil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation

Olmesartan medoxomil should be used with caution in several clinical situations.

- Pregnancy: contraindicated due to risk of fetal toxicity. - Renal impairment: dose adjustment may be needed. - Hyperkalemia: monitor serum potassium levels. - Concomitant diuretics: may increase risk of hypotension. - Drug‑induced liver injury: discontinue if liver enzymes rise markedly. - Store at ambient temperature: keep in original packaging, protect from moisture.

Olmesartan medoxomil can interact with several other medicines.

Major Interactions (Avoid): - Aliskiren combined with ACE inhibitors or ARBs in diabetic patients. - Potassium‑sparing diuretics (e.g., spironolactone) – risk of hyper‑kalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihyol -     ");